Retour aux projets

17517.2 PFLS-LS

17517.2 PFLS-LS

Résumé

Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway

Textes supplémentaires

Abstract

Cellestia Biotech is developing first-in class oral small molecule inhibitor of the Notch pathway with a mechanism of action completely different from current therapies(GSIs and Mabs) in development to target this pathway. |The goal of this project is:|i) To dissect the mechanism of action of the novel inhibitor of Notch at molecular level.|ii) To explore the invivo anti-tumor efficacy, with a focus on Notch driven cancers that cannot be adressed by the current therapies.|

Participants

Rajwinder Lehal

Wirtschaftspartner

raj.lehal@cellestia.com

Cellestia Biotech AG CHE-162.364.457 Rajwinder Lehal Hochbergerstr. 60C 4057 Basel BS CH

Freddy Radtke

Kontaktperson

freddy.radtke@epfl.ch

EPFL SV ISREC UPRAD Life Science Faculty Freddy Radtke Station 19 1015 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2015-03-31
Date de fin
2016-09-30
Coûts totaux approuvés
CHF 250056.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%